Compare Hims and Hers Health Inc (HIMS) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Hims and Hers Health Inc vs TG Therapeutics Inc — how do they compare? Hims and Hers Health Inc trades at $30.87 (market cap $6.55B), while TG Therapeutics Inc trades at $55.24 (market cap $8.16B). The key difference: TG Therapeutics Inc is the larger of the two by market cap, and TG Therapeutics Inc is trading nearer its 52-week high, Hims and Hers Health Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Hims and Hers Health Inc for 21 Days and TG Therapeutics Inc for 16 Days on average.
| HIMS | TGTX | |
|---|---|---|
Market Cap | $6.55B | $8.16B |
Volume | 14,842,814 | 1,735,121 |
Sector | Health | Health |
52-Week High | $62.76 | $59.06 |
52-Week Low | $14.52 | $26.94 |
Typical Hold Time | 21 Days | 16 Days |
Enterprise Value | $7.25B | $8.37B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Hims & Hers Health trades at $30.12, up 1.96% on the day, amid a bearish technical outlook and mixed fundamentals. The stock faces headwinds from a securities class action lawsuit related to an FTC complaint, with multiple law firms alerting investors ahead of a November 2, 2026 deadline. Financially, revenue grew to $2.35 billion in 2025, but net income turned negative in 2026, with a net loss of $142 million and a profit margin of -5.51%. Analyst consensus is a 'Hold' with a $32.17 price target, indicating limited upside from current levels.
The outlook for HIMS is cautious due to legal overhangs and profitability challenges. Investment opportunities hinge on resolving regulatory issues and returning to earnings growth, but risks include prolonged litigation, competitive pressures, and execution missteps. The stock's high valuation multiples, such as a P/E of 57.14, add vulnerability if growth disappoints.
TG Therapeutics (TGTX) trades at $54.80, up 3.49% today, but faces a bearish technical signal with recent earnings misses. Revenue growth is strong, with 2026 guidance raised to $950M for BRIUMVI, and net income margins exceed 55%. However, cash flow was negative in 2025, and a shareholder litigation investigation adds near-term uncertainty.
The outlook is mixed: analyst consensus is bullish with an $80.50 price target, but execution risks and earnings volatility persist. Upside hinges on BRIUMVI market share gains and subcutaneous formulation progress, while legal and competitive pressures pose threats to shareholder value.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Hims and Hers Health Inc
Hims & Hers is a multi-specialty telehealth platform that provides personalized health and wellness products. It offers access to medical providers and treatments for hair loss, sexual health, and skincare.
Read more on HIMS →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
